4 completed, 4 recruiting, 3 unknown, 1 active not recruiting. 12 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 4, Recruiting 4, Unknown 3, Active not recruiting 1 |
| Phase 2 | 4 | Recruiting 3, Completed 1 |
Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma INCB161734, Placebo, Investigator's choice of chemotherapy - Solid Tumors | Phase 3 | Recruiting | Incyte Corporation | 588 | 2026-04-09 | 2026-11-13 |
| A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer OT-101, mFOLFIRINOX - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Oncotelic Inc. | 455 | 2024-05-01 | 2024-08-13 |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month - Stage III Colon Cancer | Phase 2 / Phase 3 | Recruiting | NRG Oncology | 1912 | 2022-07-08 | 2026-11-04 |
| AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Nab paclitaxel plus gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 300 | 2021-09-01 | 2022-01-28 |
| Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer mFOLFIRINOX, mFOLFOX 6 - Colon Cancer Stage III | Phase 2 / Phase 3 | Recruiting | Chungnam National University Hospital | 308 | 2021-07-06 | 2026-03-19 |
| Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. Nab paclitaxel, Gemcitabine, mFOLFIRINOX - Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 600 | 2021-04-01 | 2021-04-08 |
| Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) PAXG, mFOLFIRINOX, short-course chemotherapy - Pancreas Ductal Adenocarcinoma | Phase 3 | Active not recruiting | Associazione Italiana per lo Studio del Pancreas | 261 | 2020-11-03 | 2025-04-09 |
| Brazilian Total Neoadjuvant Therapy Trial Folfirinox - Colorectal Neoplasms | Phase 3 | Unknown | Hospital Israelita Albert Einstein | 150 | 2020-02-20 | 2023-10-11 |
| Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer AG regimen, mFolfirinox - Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy | Phase 3 | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 324 | 2018-10-20 | 2025-05-13 |
| Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours GEMCIS, mFolfirinox - Bile Duct Cancer | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 191 | 2015-12-15 | 2022-02-24 |
| Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma mFolfirinox, Gemcitabine - Pancreatic Adenocarcinoma (Ductal Adenocarcinoma) | Phase 3 | Completed | UNICANCER | 493 | 2012-04-16 | 2022-01-04 |
| Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer mFolfirinox, Radiotherapy 50 Gy, Capecitabine - Cancer of the Rectum | Phase 3 | Completed | UNICANCER | 461 | 2012-01-01 | 2025-06-12 |
Colonic Neoplasms (2) · Pancreatic Neoplasms (2) · Rectal Neoplasms (2) · Bile Duct Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasms (1)
Fudan University (2) · UNICANCER (2) · Associazione Italiana per lo Studio del Pancreas (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Chungnam National University Hospital (1) · Hospital Israelita Albert Einstein (1) · Incyte Corporation (1) · NRG Oncology (1) · Oncotelic Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
France (4) · Canada (3) · United States (3) · China (2) · Italy (2) · Puerto Rico (2) · South Korea (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Denmark (1) · Finland (1) · Georgia (1) · Germany (1)
Diogo Gomes, MD (1) · Jean-Marc Phelip, PhD (1) · Kyung Ha Lee (1) · Michele Reni, MD (1) · Tingbo Liang, MD PhD (1) · Xian-Jun Jun, M.D., Ph.D. (1) · Xian-Jun Yu, MD, PhD (1)
PMID 30575490, PMID 33862000, PMID 34662180, PMID 36048453, PMID 38553680, PMID 41275879, PMID 42546248, PMID 42733563
2015 (1), U10CA180868 (1)